Skip to main content

Hyperuricemia as a prognostic marker for long-term outcomes in patients with myocardial infarction with nonobstructive coronary arteries



Hyperuricemia (HUA) has been proved as a predictor of worse outcomes in patients with coronary artery disease. Here, we investigated the prognostic value of HUA in a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA).


A total of 1179 MINOCA patients were enrolled and divided into HUA and non-HUA groups. HUA was defined as a serum uric acid level ≥ 420 μmol/L in men or ≥ 357 μmol/L in women. The primary study endpoint was a composite of major adverse cardiovascular events (MACE), including all-cause death, nonfatal MI, nonfatal stroke, revascularization, and hospitalization for unstable angina or heart failure. Kaplan–Meier, Cox regression, and receiver-operating characteristic analyses were performed.


Patients with HUA (prevalence of 23.5%) had a significantly higher incidence of MACE (18.7% vs. 12.8%; p = 0.015) than patients without during the median follow-up of 41.7 months. HUA was closely associated with an increased risk of MACE even after multivariable adjustment (hazard ratio 1.498, 95% confidence interval: 1.080 to 2.077; p = 0.016). HUA remained a robust risk factor of MACE after propensity score matching analysis. Moreover, HUA showed an area under the curve (AUC) of 0.59 for predicting MACE. Incorporation of HUA to the thrombolysis in myocardial infarction (TIMI) score yielded a significant improvement in discrimination for MACE.


HUA was independently associated with poor prognosis after MINOCA. Routine assessment of HUA may facilitate risk stratification in this specific population.


Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality of cardiovascular diseases (CVD) worldwide [1], and recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) has been increasingly recognized due to the widespread use of coronary angiography. Among all AMIs, patients with MINOCA account for 5% to 10% and they are younger and more often women compared to those with AMI and obstructive coronary artery disease [2,3,4,5]. Several studies have showed that the prognosis of MINOCA is not necessarily benign and patients with MINOCA are still at considerable risks for long-term cardiovascular (CV) events despite the optimal medical therapies [6,7,8,9]. Therefore, it is of necessity to find potential residual risk factors and improve prognosis for MINOCA population.

Serum uric acid (UA) is the final product of purine metabolism catalyzed by xanthine oxidase [10]. Elevated UA levels are closely linked with hypertension, diabetes, obesity, metabolic syndrome, and kidney diseases [11,12,13,14]. More importantly, emerging evidence indicates that hyperuricemia (HUA) is commonly seen and is an independent predictor of mortality and adverse CV events in general population [15,16,17,18,19]. Recent studies further verified the prognostic value of HUA in various subgroups with coronary artery disease (CAD), including stable CAD, acute coronary syndrome (ACS), and those undergoing percutaneous coronary intervention (PCI) [20,21,22,23,24,25,26], whereas some studies failed to confirm this association [27, 28]. Despite these data, few of them have addressed the implications of HUA in MINOCA, and the impact of HUA on long-term outcomes after MINOCA remains unclear. Here, we explored the prognostic value of HUA in MINOCA patients, and investigated whether it could improve risk stratification in this specific population.


Study population

This was a single-center, prospective and observational cohort study of patients with MINOCA. From January 2015 to December 2019, a total of 23,460 unique AMI patients with coronary angiogram were consecutively hospitalized in Fuwai hospital, including non ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Patients were diagnosed with MINOCA if they met the 4th universal definition of AMI [29] and the coronary angiography did not show a stenosis of ≥ 50% in epicardial coronary arteries [2]. Patients were excluded due to: (1) presence of obstructive CAD (n = 21,696); (2) prior revascularization (n = 312); (3) thrombolytic therapy for STEMI since the coronary lesion may be affected by thrombolysis (n = 126); (4) alternate explanations for elevated troponin rather than coronary-related causes (e.g., acute heart failure, myocarditis, pulmonary embolism, takotsubo syndrome, n = 46); (5) lack of detailed baseline data (n = 33); (6) lost at follow up (n = 68). As a result, 1179 eligible MINOCA patients were enrolled into the final analysis (Fig. 1). Patients were prescribed the evidence-based secondary therapies, including dual anti-platelet therapy (DAPT), statins, β-blocker, and angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARB) [30, 31]. This study was approved by the Ethics Committee of Fuwai hospital and complied with the Declaration of Helsinki. All enrolled subjects provided the written informed consent.

Fig. 1
figure 1

Study flowchart

Data collection

Patients’ baseline data were collected and verified from medical records. The blood samples were routinely collected from cubital vein at fasting conditions for biochemical measurement during first 48 h since admission. The plasma concentrations of uric acid (UA), fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), creatinine, and high-sensitive C-reactive protein (hs-CRP) were tested via an automatic biochemistry analyzer. Specifically, UA was analyzed with an automated biochemical analyzer (Hitachi 7150, Tokyo, Japan) in an enzymatic assay using a UA commercial kit (uricase-peroxidase method). A validated standard of UA was used for calibration, and the coefficient of variation of repetitive measurements was < 10%. The N-terminal po-B-type natriuretic peptide (NT-proBNP) at admission and peak cardiac troponin I (TnI) values were recorded. The left ventricular ejection fraction (LVEF) was measured by echocardiography using biplane Simpson method. The Thrombolysis in Myocardial Infarction (TIMI) score was calculated since admission as previously described [32, 33].

Definitions and outcomes

In line with previous studies, hyperuricemia (HUA) was defined as a serum UA level ≥ 420 μmol/L (7.0 mg/dL) in males and ≥ 357 μmol/L (6.0 mg/dL) in females [10]. Diabetes mellites (DM) was defined with FBG ≥ 7.0 mmol/L, 2-h plasma glucose ≥ 11.1 mmol/L, or having known DM. Hypertension was defined as repeated blood pressure ≥ 140/90 mmHg or use of anti-hypertensive drugs. Dyslipidemia was diagnosed by past history or having LDL-C ≥ 3.4 mmol/L, HDL-C < 1.0 mmol/L, or TG ≥ 1.7 mmol/L.

The primary study endpoint was a composite of major adverse cardiovascular events (MACE), including all-cause death, nonfatal MI, revascularization, nonfatal stroke, and hospitalization for unstable angina (UA) or heart failure (HF). The MACE was assessed as time to first event. The secondary endpoints included each component of MACE and the composite “hard” endpoint of death, nonfatal MI, revascularization, and nonfatal stroke. Reinfarction was diagnosed according to the 4th universal definition of MI [29]. Revascularization was performed at the operator’s discretion due to recurrent ischemia and progression of coronary lesion. Stroke was defined by the presence of neurological dysfunction and vascular brain injury caused by cerebral ischemia or hemorrhage [34]. Hospitalization for UA or HF reflected the clinical status and quality of life after AMI. Patients were regularly and actively followed up at clinics or through telephone contact at 6 month intervals by a team of independent well-trained researchers. The endpoints were confirmed by at least two professional cardiologists.

Statistical analysis

Data were expressed as mean ± standard deviation (SD) or median with interquartile range for continuous variables and numbers with percentages for categorical variables. Differences were assessed using Student’s t test or Mann–Whitney U test for continuous variables and Pearson’s χ2 or Fisher’s exact test for categorical variables. Cumulative hazard ratio of MACE between HUA and non-HUA groups were showed by Kaplan–Meier analysis and compared using the log-rank test. The univariable and multivariable Cox proportional regression analyses were used to identify association of HUA with CV outcomes. The risk of MACE was adjusted by multiple clinically relevant variables, including age, sex, BMI, MI classification (NSTEM or STEMI), hypertension, diabetes and dyslipidemia. Hazard ratio (HR) with 95% confidence interval (CI) were calculated. The effect of HUA on MACE risk was further assessed by propensity score matching (PSM) and sex subgroup analyses, in which detailed explanations were shown in the supplementary data. Discrimination was defined with areas under the curve (AUC) using a receiver-operating characteristic curve (ROC) analysis. The AUC values were classified as small (0.56–0.63), moderate (0.64–0.70) or strong (≥ 0.71) [35] and compared by Delong’s test [36]. To evaluate the incremental predictive value of HUA for MACE, a combined risk model was generated by incorporating HUA into the original TIMI risk score based on multivariate Cox model. A two-sided analysis with a P value < 0.05 was considered statistically significant. Data were analyzed using SPSS V.22.0 (SPSS Inc., Chicago, USA) and R language V.3.6.3 (Feather Spray).


Baseline characteristics

Patients were divided into normouricemia group and HUA group. The incidence of HUA was 23.5% in all MINOCA patients (Fig. 1). The plasma UA concentrations were normally distributed in the population (Additional file 1: Fig. S1). As shown in Table 1, patients with HUA were younger and more often male. They had higher BMI, higher percent of STEMI, higher TG and lower HDL-C. There were no significant differences in the rate of hypertension, diabetes, dyslipidemia, prior MI and in-hospital medication. Also, the Killip class, LVEF level, TIMI risk score, and values of FBG, TC, LDL-C, creatinine, hs-CRP, NT-proBNP, and peak TnI were similar between the groups. In this regard, despite the differences in demographics, the comorbidities and general CV risk profiles were comparable in patients with or without HUA.

Table.1 Baseline characteristics and clinical outcomes in MINOCA patients with or without hyperuricemia

Association between HUA and outcomes

During the median follow-up of 41.7 months, 168 patients developed MACE (18 died, 41 had recurrent MI, 46 underwent revascularization, 12 suffered stroke, 71 was hospitalized for UA and 48 hospitalized for HF) (Table 1). The profiles in patients with or without MACE were also compared and those who developed MACE had more UA levels (Additional file 1: Table S1). Consistently, patients with HUA had a significantly higher incidence of MACE than patient without (18.7% vs. 12.8%; p = 0.015) (Table 1). The rate of the composite “hard” endpoint of death, recurrent MI, revascularization or stroke also increased in HUA group (11.8% vs. 7.6%; p = 0.029). In addition, the Kaplan–Meier analysis showed that the cumulative incidence of MACE was significantly higher in patients with HUA (log rank p = 0.015) (Fig. 2). As for each component of MACE, the incidence of death, MI, stroke or revascularization were slightly higher in HUA group, but no significant differences were observed. Interestingly, patients with HUA had a significantly higher rate of HF (Table 1).

Fig. 2
figure 2

Incidence of MACE in MINOCA patients with or without hyperuricemia. Kaplan–Meier analysis showing the cumulative hazard ratio of MACE in patients with MINOCA with or without hyperuricemia

At multivariate Cox analysis, the HUA was significantly associated with an increased risk of MACE after multivariable adjustment (HR 1.498, 95% CI: 1.080–2.077, p = 0.016) (Table 2). As a continuous variable, the UA levels also correlated with the adjusted risk of MACE (for per 1SD increase in UA, HR 1.012, 95% CI: 1.006–1.018, p = 0.005). We further analyzed the potential risk factors and HUA remained an independent predictor of MACE (Additional file 1: Table S2). This association was still significant in the 273 matched pairs of MINOCA patients with or without HUA after PSM (Additional file 1: Table S3), indicating that HUA may be a residual risk factor for MINOCA patients. The UA levels and CV outcomes were also compared between sexes. Men had higher UA than women while no sex gaps in prognosis were observed (Additional file 1: Table S4).

Table.2 Association between uric acid levels and the risk of MACE

Predictive value of HUA for MACE

The ROC analysis showed the discriminatory ability of HUA (AUC 0.59) and TIMI risk score (AUC 0.67) for MACE prediction (Fig. 3). When adding HUA to the original TIMI score, the combined model enabled a more accurate prediction of MACE (AUC 0.72) and accordingly yielded a significant improvement in risk prediction (ΔAUC 0.05, p = 0.019 by DeLong’s test).

Fig. 3
figure 3

Model improvement in predicting MACE. Receiver operating characteristic curves showing the predictive value of hyperuricemia (HUA), TIMI risk score, and the combined model incorporating HUA and TIMI score. TIMI: Thrombolysis in Myocardial Infarction, AUC: area under the curve


In the present study, we found that HUA was frequently seen and was independently associated with worse prognosis in patients with MINOCA. Moreover, HUA improved the outcome prediction when added to a well-established risk score. These data indicate that assessment of serum UA levels may provide valuable prognostic information, and further support the utility of HUA for risk stratification in the contemporary real-world management of MINOCA.

MINOCA represents a distinct clinical entity with multiple underlying mechanisms, including plaque rupture, erosion, thromboembolism, coronary spasm, dissection, and myocardial supply/demand mismatch. Some non-ischemic diseases such as myocarditis may also mimic the presentation of MINOCA [5]. More recently, the term MINOCA has been used to primarily describe patients with coronary-related ischemia. We used this criteria and established a long-term cohort of MINOCA with a relatively large sample size. The prevalence of MINOCA is 5.1% in our study, which is close to the estimated 6% in all AMIs [4]. As reported, patients with MINOCA were more likely to be younger, female, and had fewer comorbidities. Nearly one-third of MINOCA would present with STEMI [4]. We described the clinical profiles of MINOCA as well. Also, we found that the prognosis of MINOCA was not a trivial thing. During the median follow-up of 3.5 years, 1.5% of MINOCA patients died and 14.2% of them developed MACE. Similarly, previous studies showed that these patients were still at considerable risk for long-term mortality and adverse CV events [4,5,6,7,8,9]. Hence, it is critical to find potential risk factors contributing to this residual CV risk and further improve healthcare for this population.

Over the past decade, elevated levels of serum UA have not only been considered as a biomarker for gout but also an important risk factor for CVD, kidney disease, and metabolic disorders such as hypertension and diabetes [10,11,12,13,14]. Recently, the relationship between HUA and CV outcomes has received a large amount of attention. As reported, early onset of HUA was associated with increased CVD and mortality risk in the general population [15]. A large cohort study showed that stable high UA was correlated with an increased higher risk of MI [16]. Another study also proved a strong relationship between HUA and silent MI in healthy community dwellers [17]. A Mendelian randomization study revealed that high UA was causally related to worse outcomes, especially sudden cardiac death [18]. A meta-analysis of 14 prospective cohort studies found that for every 1 mg/dL increase in serum UA levels, the overall risk of CAD and all-cause mortality increased by 20% and 9%, respectively [19]. Apart from the general population, recent studies further confirmed an independent association of HUA with long-term CV risks in different cohorts with CAD (e.g., stable CAD, ACS, AMI, or those treated with PCI), suggesting that HUA significantly correlated with the increased CV risk [20,21,22,23,24,25,26]. This is not only the case in acute setting, but also in the longer term after recovery from ACS or after revascularization. Of note, some conflicting results have emerged regarding the causal effect of HUA on mortality and CV outcomes, however, the most recent studies and meta-analyses mentioned above support HUA as a residual CV risk factor.

To our knowledge, data regarding the implications of HUA in MINOCA population are scarce. A recent study enrolled 249 patients with MINOCA and reported that HUA was associated with adverse outcomes [37]. Here, we addressed this issue and conducted a larger scale and longitudinal analysis of MINOCA cohort. Consistently, we found that patients with HUA had a poorer prognosis after MINOCA. Those with HUA had a 1.49-fold higher hazard ratio of MACE compared to those without even after multivariable adjustment. HUA remained a strong predictor of MACE at PSM analysis. Further, HUA significantly improved the accuracy of risk prediction when added to the TIMI score. Apart from the composite endpoint, we found that the incidence of death, MI, stroke or revascularization did not differ significantly between HUA and non-HUA groups. There might be two reasons. First, the effect of HUA on each event may be partially attenuated by the overall improvement in clinical management of AMI and wide use of secondary prevention treatments. Second, the sample size and number of each ischemic event may be limited in this single-center study. Moreover, we found that the rate of HF was much higher in the HUA group, suggesting a role of HUA in HF progression after MINOCA. A meta-analysis also revealed that HUA increased the risk of incident HF and adverse events in HF patients [38]. Taken together, our data supported the concept that elevated UA contributes to residual CV risk and further extended the prognostic value of HUA to MINOCA patients. Given the observational design of our study, our findings should be validated by a larger randomized study confirming the causal relationship between HUA and CV outcomes after MINOCA.

The underlying mechanisms linking HUA and poor CV outcomes are manifold, and several reasons have been proposed. It is found that intracellular and mitochondrial UA aggravates atherosclerosis by releasing free radicals and inducing oxidative stress [39]. UA can also trigger inflammatory pathways, induce vascular inflammation, and further promote atherogenesis [40]. In addition, UA can penetrate endothelium, reduce synthesis and release of NO, and thus lead to endothelial dysfunction and vasoconstriction [41, 42]. Moreover, UA can promote insulin resistance and metabolic syndrome [43, 44]. All these processes may finally contribute to the development and progression of atherosclerosis, and result in a higher risk of CV events. Our study provided a rationale for identifying MINOCA patients who may benefit from UA-lowering therapies. However, the safety and long-term benefit of UA-targeted therapies in MINOCA with HUA remain unclear and warrant more research in the future.


Some limitations should be mentioned. First, the percentage of women was relatively low in our cohort, possibly due to the large proportion of men in all AMIs treated in our center and a lower rate for women to receive coronary angiography. Given the potential selection bias in single-center studies, future nationwide registry cohorts of MINOCA are warranted to validated our findings. Second, we did not capture and record the exact mechanism for every MINOCA patient. The association between etiology of MINOCA and outcomes should be further investigated. Third, despite multivariate adjustment and subgroup analyses were performed, there might be other unmeasured confounders that may affect the prognosis. Fourth, the serum UA levels were only measured at baseline, and the follow-up levels of UA may also be clinically significant.


Hyperuricemia was an independent predictor of long-term MACE after MINOCA. In clinical practice, routine assessment of serum UA levels may help to identify high-risk patients with MINOCA and thus facilitate the pre-emptive decision making.

Availability of data and materials

The datasets used and analyzed during the current study available from the corresponding author on reasonable request.



Acute coronary syndrome;


Acute myocardial infarction


Areas under the curve


Coronary artery disease


Confidence interval




Hazard ratio




Major adverse cardiovascular event


Myocardial infarction with nonobstructive coronary arteries


Percutaneous coronary intervention


Propensity score matching


Receiver-operating characteristic curve


Standard deviation


Thrombolysis in myocardial infarction


Uric acid


  1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA). J Int Med. 2013;273:182–5.

    Article  Google Scholar 

  3. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38:143–53.

    Article  PubMed  Google Scholar 

  4. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861–70.

    Article  CAS  PubMed  Google Scholar 

  5. Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J. 2015;36:475–81.

    Article  PubMed  Google Scholar 

  6. Bainey KR, Welsh RC, Alemayehu W, Westerhout CM, Traboulsi D, Anderson T, et al. Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. Int J Cardiol. 2018;264:12–7.

    Article  PubMed  Google Scholar 

  7. Andersson HB, Pedersen F, Engstrøm T, Helqvist S, Jensen MK, Jørgensen E, et al. Long-term survival and causes of death in patients with ST-elevation acute coronary syndrome without obstructive coronary artery disease. Eur Heart J. 2018;39:102–10.

    Article  PubMed  Google Scholar 

  8. Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, et al. Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circ Cardiovasc Interv. 2014;7:285–93.

    Article  CAS  PubMed  Google Scholar 

  9. Abdu FA, Liu L, Mohammed AQ, Luo Y, Xu S, Auckle R, et al. Myocardial infarction with non-obstructive coronary arteries (MINOCA) in Chinese patients: clinical features, treatment and 1 year follow-up. Int J Cardiol. 2019;287:27–31.

    Article  PubMed  Google Scholar 

  10. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759–66.

    Article  CAS  PubMed  Google Scholar 

  11. Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens. 2006;20:937–45.

    Article  CAS  PubMed  Google Scholar 

  12. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31:361–2.

    Article  CAS  PubMed  Google Scholar 

  13. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33:1729–41.

    Article  CAS  PubMed  Google Scholar 

  14. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.

    Article  CAS  PubMed  Google Scholar 

  15. Li L, Zhao M, Wang C, Zhang S, Yun C, Chen S, et al. Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. Clin Res Cardiol. 2021.

    Article  PubMed  Google Scholar 

  16. Ahmad MI, Dutta A, Anees MA, Soliman EZ. Interrelations between serum uric acid, silent myocardial infarction, and mortality in the general population. Am J Cardiol. 2019;123:882–8.

    Article  CAS  PubMed  Google Scholar 

  17. Tian X, Zuo Y, Chen S, Wang A, Li H, He Y, et al. Associations between changes in serum uric acid and the risk of myocardial infarction. Int J Cardiol. 2020;314:25–31.

    Article  PubMed  Google Scholar 

  18. Kleber ME, Delgado G, Grammer TB, Silbernagel G, Huang J, Krämer BK, et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol. 2015;26:2831–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16:207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ndrepepa G, Braun S, King L, Hadamitzky M, Haase HU, Birkmeier KA, et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism. 2012;61:1780–6.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang C, Jiang L, Xu L, Tian J, Liu J, Zhao X, et al. Implications of hyperuricemia in severe coronary artery disease. Am J Cardiol. 2019;123:558–64.

    Article  CAS  PubMed  Google Scholar 

  22. Magnoni M, Berteotti M, Ceriotti F, Mallia V, Vergani V, Peretto G, et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017;240:25–9.

    Article  PubMed  Google Scholar 

  23. Lopez-Pineda A, Cordero A, Carratala-Munuera C, Orozco-Beltran D, Quesada JA, Bertomeu-Gonzalez V, et al. Hyperuricemia as a prognostic factor after acute coronary syndrome. Atherosclerosis. 2018;269:229–35.

    Article  CAS  PubMed  Google Scholar 

  24. Tscharre M, Herman R, Rohla M, Hauser C, Farhan S, Freynhofer MK, et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis. 2018;270:173–9.

    Article  CAS  PubMed  Google Scholar 

  25. Kaya MG, Uyarel H, Akpek M, Kalay N, Ergelen M, Ayhan E, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109:486–91.

    Article  CAS  PubMed  Google Scholar 

  26. Guo W, Yang D, Wu D, Liu H, Chen S, Liu J, et al. Hyperuricemia and long-term mortality in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Ann Transl Med. 2019;7:636.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Maloberti A, Bossi I, Tassistro E, Rebora P, Racioppi A, Nava S, et al. Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter. Nutr Metab Cardiovasc Dis. 2021;31:1501–8.

    Article  CAS  PubMed  Google Scholar 

  28. Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically determined uric acid and the risk of cardiovascular and neurovascular diseases: a Mendelian randomization study of outcomes investigated in randomized trials. J Am Heart Assoc. 2019;8: e012738.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. J Am Coll Cardiol. 2018;72:2231–64.

    Article  PubMed  Google Scholar 

  30. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2016;37:267–315.

    Article  CAS  PubMed  Google Scholar 

  31. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.

    Article  PubMed  Google Scholar 

  32. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–42.

    Article  CAS  PubMed  Google Scholar 

  33. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031–7.

    Article  CAS  PubMed  Google Scholar 

  34. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol. 2018;71:1021–34.

    Article  PubMed  Google Scholar 

  35. Ma H, Bandos AI, Rockette HE, Gur D. On use of partial area under the ROC curve for evaluation of diagnostic performance. Stat Med. 2013;32:3449–58.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Delong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics. 1988;44:837–45.

    Article  CAS  Google Scholar 

  37. Mohammed AQ, Abdu FA, Liu L, Zhang W, Yin G, Xu Y, et al. Hyperuricemia predicts adverse outcomes after myocardial infarction with non-obstructive coronary arteries. Front Med (Lausanne). 2021;8: 716840.

    Article  Google Scholar 

  38. Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15–24.

    Article  CAS  PubMed  Google Scholar 

  39. Biscaglia S, Ceconi C, Malagu M, Pavasini R, Ferrari R. Uric acid and coronary artery disease: an elusive link deserving further attention. Int J Cardiol. 2016;213:28–32.

    Article  PubMed  Google Scholar 

  40. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27:1174–81.

    Article  CAS  PubMed  Google Scholar 

  41. Prasad M, Matteson EL, Herrmann J, Gulati R, Rihal CS, Lerman LO, et al. Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women. Hypertension. 2017;69:236–42.

    Article  CAS  PubMed  Google Scholar 

  42. Ko J, Kang HJ, Kim DA, Kim MJ, Ryu ES, Lee S, et al. Uric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative stress and glycocalyx shedding. FASEB J. 2019;33:13334–45.

    Article  CAS  PubMed  Google Scholar 

  43. Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925–32.

    Article  CAS  PubMed  Google Scholar 

  44. DeBosch BJ, Kluth O, Fujiwara H, Schurmann A, Moley K. Earlyonset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642.

    Article  CAS  PubMed  Google Scholar 

Download references




This work was supported by National Natural Science Foundation of China (81670415).

Author information

Authors and Affiliations



WM and SG conceived and designed the study. WM, SG, SH and JY performed data analysis and interpretation. WM and SG drafted the manuscript. JY and MY reviewed and gave final approval of the version to be published. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jiansong Yuan or Mengyue Yu.

Ethics declarations

Ethics approval and consent to participate

Written informed consent was obtained from all participants. All work was approved by the Ethics Committee of Fuwai hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Table S1. Clinical risk factors in patients with or without MACE. Table S2. Potential clinical risk factors for MACE in MINOCA patients. Table S3. Distribution of clinically relevant variables and outcomes before and after propensity score matching in patients with or without hyperuricemia. Table S4. Uric acid and CV outcomes between sex groups. Fig S1. Distribution of the serum uric acid in MINOCA patients.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ma, W., Gao, S., Huang, S. et al. Hyperuricemia as a prognostic marker for long-term outcomes in patients with myocardial infarction with nonobstructive coronary arteries. Nutr Metab (Lond) 18, 107 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Myocardial infarction with nonobstructive coronary arteries (MINOCA)
  • Hyperuricemia
  • Cardiovascular outcomes